Characteristics of TCRζ, ZAP-70, and FcɛRIγ Gene Expression in Patients with T- and NK/T-Cell Lymphoma

Liao, Ziwei; Zhou, Lingling; Wang, Chunyan; He, Zuhua; Wang, Xu; Luo, Xiaodan; Chen, Shaohua; Yang, Lijian; H, Tan; Li, Yangqiu

doi:10.1089/dna.2014.2693

Cited by 10 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such deficiency in CD3 gene expression levels might be, at least, a part of the reason for the reduction in T cell activation in AML. Similar findings were also reported in CML, CLL, and lymphomas (Huang et al, 2012;Zha et al, 2012b;Liao et al, 2014). Therefore, enhancing CD3 expression may reactive the T cell activation functions and reverse the immunodeficiency in leukemia patients.…”

Section: Resultssupporting

confidence: 84%

Enhancement of the TCRζ Expression, Polyclonal Expansion, and Activation of T Cells from Patients with Acute Myeloid Leukemia After IL-2, IL-7, and IL-12 Induction

Shi

Chen

Zha

et al. 2015

DNA and Cell Biology

Self Cite

View full text Add to dashboard Cite

Defective T cell receptor (TCR) signaling resulting in lower T cell function plays a crucial role in the pathogenesis of T cell immunodeficiency in leukemia. Previous studies have indicated that lower TCRf levels are a common characteristic of patients with leukemia, and upregulating TCRz could partially recover T cell function. In this study, we characterized the effect of the stimulating factor induction on the TCRf, Zap-70, and FceRIc levels, IFN-g secretion, and the distribution and clonal expansion of TCR Vb subfamilies in CD3 + T cells sorted from peripheral blood from acute myeloid leukemia (AML) patients. The induction included single stimulating factor or a combination with different cytokines (IL-2, IL-7, IL-2 + IL-7, IL-7 + IL-12, CD3, CD3 + CD28 antibody, CD3 + CD28 antibody + IL-2, and CD3 + CD28 antibody + IL-7) at 72 h. The results showed that increased TCRf and Zap-70 levels with deceased FceRIc in T cells after induction, and different responses to cytokine in T cell from different cases may indicate the heterogeneity of T cells and different immune statuses in different AML cases. Increased IFN-g levels in T cells from AML patients were detected after induction in the IL-12 + IL-7, CD3 + CD28 + IL-2, and CD3 + CD28 + IL-7 groups. Moreover, the number of TCR Vb subfamily T cells expressed was increased; however, all of the TCR Vb subfamily T cells in the AML patients could not be completely recovered after induction. In conclusion, the cytotoxicity and activation function of T cells could be enhanced after induction by different stimuli accompanied by an increase in TCRf and Zap-70 and recovery of the TCR Vb repertoire in AML patients.

show abstract

Section: Resultssupporting

confidence: 84%

Enhancement of the TCRζ Expression, Polyclonal Expansion, and Activation of T Cells from Patients with Acute Myeloid Leukemia After IL-2, IL-7, and IL-12 Induction

Shi

Chen

Zha

et al. 2015

DNA and Cell Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, T‐cell‐mediated cellular immunity can cause target cells to lyse and release antigens 12,13 . Defective T or NK cell functions such as abnormal expression of certain signaling molecules have a crucial influence on the formation of NKTL 14 . It has also been reported that decreased expression of TCRζ, ZAP‐70 and FcɛRIγ genes in NKTL leads to a lower immune state, which results in disease progression 15 .…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T‐cell lymphoma: A randomized, controlled, open‐label, multicenter study

Zhang

Wang

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

To compare the efficacy and safety of radiotherapy (RT) and chemotherapy of pegaspargase, gemcitabine, cisplatin and dexamethasone (DDGP) combined with RT in newly diagnosed stage I‐II natural killer/T‐cell lymphoma (NKTL), we designed a randomized, controlled, open‐label, multicenter clinical trial. Data from 65 stage I‐II NKTL patients whose diagnoses were confirmed using immunohistochemistry were enrolled from January 2011 to December 2013 in the First Affiliated Hospital of Zhengzhou University. Patients were randomly divided into the RT group (n = 35) and the DDGP combined with RT group (n = 30). There was a difference between the Eastern Cooperative Oncology Group (ECOG) score in the two arms (P = .013). The complete response rate (CRR) and objective response rate (ORR) of DDGP combined with RT group were superior to those in the RT group (CRR: 73.3% vs 48.6%; ORR: 83.3% vs 60.0%, respectively). The 5‐year progression‐free survival (PFS) rate and overall survival (OS) rate in the DDGP combined with RT group were higher than those in the RT group (82.9% vs 56.5% for PFS, P = .023; 85.7% vs 60.4% for OS, P = .040), and treatment methods and lactate dehydrogenase were independent risk factors. Myelosuppression (P < .001), gastrointestinal reactions (P < .001), abnormal liver function (P = .007), coagulation abnormalities (P < .001) and baldness (P < .001) were more likely to occur in the DDGP combined with RT group. In conclusion, DDGP combined with radiotherapy obviously obtained great efficacy and prolonged the survival time of patients, also the side effects were mild for stage I‐II NKTL. This trial was registered at https://register.clinicaltrials.gov as #NCT01501136.

show abstract

“…PCR was performed as described in previous studies. 30,33 Briefly, 25-μl PCRs were performed with approximately 1 μl cDNA, 0.5 μM of each primer (PD-1-for and PD-1rev for the PD-1 gene, PD-L1-for and PD-L1-rev for the PD-L1 gene, CTLA-4-for and CTLA-4-rev for the CTLA-4 gene, and β2M-for and β2M-rev for the β2-MG gene), 2.5× RealMasterMix (11.25 μl) (Tiangen, Beijing). After an initial denaturation at 95°C for 2 hours, 45 cycles consisting of 95°C for 15 minutes and 60°C for 1 hour were performed using an MJ Research DNA Engine Opticon 2 PCR cycler (BIO-RAD, USA).…”

Section: Materials and Methods Samplesmentioning

confidence: 99%

Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP

Zhong

Chen

et al. 2016

Hematology

Self Cite

View full text Add to dashboard Cite

show abstract

Characteristics of TCRζ, ZAP-70, and FcɛRIγ Gene Expression in Patients with T- and NK/T-Cell Lymphoma

Cited by 10 publications

References 35 publications

Enhancement of the TCRζ Expression, Polyclonal Expansion, and Activation of T Cells from Patients with Acute Myeloid Leukemia After IL-2, IL-7, and IL-12 Induction

Enhancement of the TCRζ Expression, Polyclonal Expansion, and Activation of T Cells from Patients with Acute Myeloid Leukemia After IL-2, IL-7, and IL-12 Induction

Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T‐cell lymphoma: A randomized, controlled, open‐label, multicenter study

Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP

Contact Info

Product

Resources

About